Top

Published in:

Open Access 01-03-2012 | Original

Effect of CGRP and sumatriptan on the BOLD response in visual cortex

Authors: Mohammad S. Asghar, Adam E. Hansen, Henrik B. W. Larsson, Jes Olesen, Messoud Ashina

Published in: The Journal of Headache and Pain | Issue 2/2012

Abstract

To test the hypothesis that calcitonin gene-related peptide (CGRP) modulates brain activity, we investigated the effect of intravenous CGRP on brain activity in response to a visual stimulus. In addition, we examined if possible alteration in brain activity was reversed by the anti-migraine drug sumatriptan. Eighteen healthy volunteers were randomly allocated to receive CGRP infusion (1.5 μg/min for 20 min) or placebo. In vivo activity in the visual cortex was recorded before, during and after infusion and after 6 mg subcutaneous sumatriptan by functional magnetic resonance imaging (3 T). 77% of the participants reported headache after CGRP. We found no changes in brain activity after CGRP (P = 0.12) or after placebo (P = 0.41). Sumatriptan did not affect brain activity after CGRP (P = 0.71) or after placebo (P = 0.98). Systemic CGRP or sumatriptan has no direct effects on the BOLD activity in visual cortex. This suggests that in healthy volunteers both CGRP and sumatriptan may exert their actions outside of the blood–brain barrier.

Available only for authorised users

Villalón CM, Olesen J (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 12:309–323, 10.1016/j.pharmthera.2009.09.003CrossRef

Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM (1983) Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 7:129–135, 10.1038/304129a0CrossRef

Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C (1985) Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett 7:213–217, 10.1016/0304-3940(85)90166-1CrossRef

McCulloch J, Uddman R, Kingman TA, Edvinsson L (1986) Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA 8:5731–5735, 10.1073/pnas.83.15.5731CrossRef

Uddman R, Edvinsson L, Ekblad E, Håkanson R, Sundler F (1986) Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept 8:1–23, 10.1016/0167-0115(86)90071-6CrossRef

Tsai SH, Tew JM, McLean JH, Shipley MT (1988) Cerebral arterial innervation by nerve fibers containing calcitonin gene-related peptide (CGRP): I. Distribution and origin of CGRP perivascular innervation in the rat. J Comp Neurol 5:435–444, 10.1002/cne.902710310CrossRef

Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 2:193–196, 10.1002/ana.410230214CrossRef

Lassen L, Haderslev P, Jacobsen V, Iversen H, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 2:54–61, 10.1046/j.1468-2982.2002.00310.xCrossRef

Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning P, Larsson HB, Olesen J, Ashina M (2011) Evidence for a vascular factor in migraine. Ann Neurol 4:635–645, 10.1002/ana.22292CrossRef

10.

Olesen J, Diener H, Husstedt I, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 3:1104–1110, 10.1056/NEJMoa030505CrossRef

11.

Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 4:1304–1312, 10.1212/01.WNL.0000286940.29755.61CrossRef

12.

Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 10:573–582, 10.1038/nrneurol.2010.127CrossRef

13.

Petersen K, Nilsson E, Olesen J, Edvinsson L (2005) Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo. Cephalalgia 6:424–432, 10.1111/j.1468-2982.2005.00869.xCrossRef

14.

Asghar MS, Hansen AE, Kapijimpanga T, van der Geest RJ, van der Koning P, Larsson HB, Olesen J, Ashina M (2010) Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology 10:1520–1526, 10.1212/WNL.0b013e3181f9626aCrossRef

15.

Kwong K, Belliveau J, Chesler D, Goldberg IE, Weisskoff RM, Poncelet BP, Kennedy DN, Hoppel BE, Cohen MS, Turner R (1992) Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci USA 6:5675–5679, 10.1073/pnas.89.12.5675CrossRef

16.

Ogawa S, Lee T, Nayak A, Glynn P (1990) Oxygenation-sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields. Magn Reson Med 4:68–78, 10.1002/mrm.1910140108CrossRef

17.

Buxton R, Wong E, Frank L (1998) Dynamics of blood flow and oxygenation changes during brain activation: the balloon model. Magn Reson Med 6:855–864, 10.1002/mrm.1910390602CrossRef

18.

Genovese C, Lazar N, Nichols T (2002) Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 4:870–878, 10.1006/nimg.2001.1037CrossRef

19.

Petersen K, Birk S, Lassen L, Kruuse C, Jonassen O, Lesko L, Olesen J (2005) The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2:139–147, 10.1111/j.1468-2982.2004.00830.xCrossRef

20.

Iversen H, Olesen J, Tfelt-Hansen P (1989) Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 6:17–24, 10.1016/0304-3959(89)90067-5CrossRef

21.

Hoge R, Atkinson J, Gill B, Crelier G, Marrett S, Pike G (1999) Investigation of BOLD signal dependence on cerebral blood flow and oxygen consumption: the deoxyhemoglobin dilution model. Magn Reson Med 11:849–863, 10.1002/(SICI)1522-2594(199911)42:5<849::AID-MRM4>3.0.CO;2-ZCrossRef

22.

Denuelle M, Boulloche N, Payoux P, Fabre N, trotter Y, Géraud G (2011) A PET study of photophobia during spontaneous migraine attacks. Neurology 76(3):213–218, 21148120, 10.1212/WNL.0b013e3182074a57, 1:STN:280:DC%2BC3M7hvF2msg%3D%3DPubMedCrossRef

23.

Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J (2005) BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 3:202–213, 10.1016/j.clpt.2004.10.001CrossRef

24.

Lassen LH, Jacobsen VB, Haderslev PA, Sperling B, Iversen HK, Olesen J, Tfelt-Hansen P (2008) Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain 6:151–157, 10.1007/s10194-008-0036-8CrossRef

25.

Lennerz JK, Rühle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K (2008) Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 3:1277–1299, 10.1002/cne.21607CrossRef

26.

Gu X, Yu L (2007) The colocalization of CGRP receptor and AMPA receptor in the spinal dorsal horn neuron of rat: a morphological and electrophysiological study. Neurosci Lett 3:237–241, 10.1016/j.neulet.2006.12.056CrossRef

27.

Yu Y, Lundeberg T, Yu LC (2002) Role of calcitonin gene-related peptide and its antagonist on the evoked discharge frequency of wide dynamic range neurons in the dorsal horn of the spinal cord in rats. Regul Pept 1:23–27, 10.1016/S0167-0115(01)00326-3CrossRef

28.

Pecile A, Guidobono F, Netti C, Sibilia V, Biella G, Braga PC (1987) Calcitonin gene-related peptide: antinociceptive activity in rats, comparison with calcitonin. Regul Pept 8:189–199, 10.1016/0167-0115(87)90007-3CrossRef

29.

Huang Y, Brodda-Jansen G, Lundeberg T, Yu LC (2000) Anti-nociceptive effects of calcitonin gene-related peptide in nucleus raphe magnus of rats: an effect attenuated by naloxone. Brain Res 8:54–59, 10.1016/S0006-8993(00)02473-2CrossRef

30.

Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 1:54–56, 10.1038/313054a0CrossRef

31.

Eftekhari S, Edvinsson L (2010) Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord 11:369–378, 10.1177/1756285610388343CrossRef

32.

Wimalawansa SJ (1996) Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17(5):533–585, 8897024, 1:CAS:528:DyaK28XmvF2hs7Y%3DPubMedCrossRef

33.

Jansen-Olesen I, Jørgensen L, Engel U, Edvinsson L (2003) In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 11:207–216, 10.1016/j.ejphar.2003.09.021CrossRef

34.

Gupta S, Mehrotra S, Avezaat CJJ, Villalón CM, Saxena PR, Maassenvandenbrink A (2006) Characterisation of CGRP receptors in the human isolated middle meningeal artery. Life Sci 6:265–271, 10.1016/j.lfs.2006.01.003CrossRef

35.

Petersen K, Birk S, Doods H, Edvinsson L, Olesen J (2004) Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 11:697–704, 10.1038/sj.bjp.0705966CrossRef

36.

Humphrey PP, Goadsby PJ (1994) The mode of action of sumatriptan is vascular? A debate. Cephalalgia 12:401–410 (discussion 393), 10.1046/j.1468-2982.1994.1406401.x, (discussion 393)CrossRef

37.

Ahn A, Basbaum A (2005) Where do triptans act in the treatment of migraine? Pain 5:1–4, 10.1016/j.pain.2005.03.008CrossRef

38.

Levy D, Burstein R, Strassman A (2005) Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 11:698–705, 10.1002/ana.20619CrossRef

39.

Goadsby P, Knight Y (1997) Direct Evidence for Central Sites of Action of Zolmitriptan (311C90). Cephalalgia 5:153–158, 10.1046/j.1468-2982.1997.1703153.xCrossRef

40.

Sakai Y, Dobson C, Diksic M, Aubé M, Hamel E (2008) Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology 2:431–439, 10.1212/01.wnl.0000299095.65331.6fCrossRef

Title: Effect of CGRP and sumatriptan on the BOLD response in visual cortex
Authors: Mohammad S. Asghar
Adam E. Hansen
Henrik B. W. Larsson
Jes Olesen
Messoud Ashina
Publication date: 01-03-2012
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 2/2012
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1007/s10194-011-0415-4

At a glance: The STEP trials

Springer Medicine

Effect of CGRP and sumatriptan on the BOLD response in visual cortex

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Interactions between migraine and tension-type headache and alcohol drinking, alcohol flushing, and hangover in Japanese

Headache prevalence and characteristics among school children as assessed by prospective paper diary recordings

Antidromic vasodilatation and the migraine mechanism

Epicrania fugax with backward radiation

Are headaches different from other chronic pains?

Management of primary chronic headache in the general population: the Akershus study of chronic headache